Evidence map›Paper›PMID 40331912›Full record

ArticleBlood2025

ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance.

Lara Wahlster, Lucy A Godley, Jason X Cheng, Michael W Drazer, Christopher R Reilly, Geraldine S Pinkus, Jared H Rowe, Nina Weichert-Leahey, R Grant Rowe, Lev Gorfinkel and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Lara WahlsterDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0001-8409-7580
Lucy A GodleyDivision of Hematology/Oncology, Lurie Children's Hospital, Northwestern Medicine, Chicago, IL.ORCID 0000-0003-1914-9158
Jason X ChengDepartment of Pathology, The University of Chicago, Chicago, IL.ORCID 0000-0002-4626-770X
Michael W DrazerSections of Hematology/Oncology and Genetic Medicine, Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL.ORCID 0000-0002-8171-4106
Christopher R ReillyDivision of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-9551-7533
Geraldine S PinkusDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jared H RoweDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-4223-4433
Nina Weichert-LeaheyDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-0351-3018
R Grant RoweDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0003-3620-2950
Lev GorfinkelDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-8781-2276
Karyn BrundigeDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0009-0006-0605-5020
Franziska WachterDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0001-9185-3612
Luana MessaDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0009-0007-2016-5389
Alan D MichelsonDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-1746-4819
Alan B CantorDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-5136-028X
Akiko ShimamuraDivision of Hematology/Oncology, Boston Children's Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-4683-9958
Jacob R BledsoeDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-2387-5462

Funding

Systems Biology of Bone Marrow Failure and MDS for Precision MedicineRC2DK122533 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FIGUEROA, MARIA EUGENIA, FLEMING, MARK D · 2019 to 2023
$6.4M
NIDDK NIH HHS RC2 DK122533
6 · The paper itself

Abstract

abstractWe report on 8 patients with ankyrin repeat domain 26 (ANKRD26)-related thrombocytopenia 2 (ANKRD26-RT) with elevated bone marrow myeloblasts and dysmegakaryopoiesis, without somatic genetic abnormalities or progression to malignancy during long-term observation, findings which may constitute inherent ANKRD26-RT biology rather than progression to myeloid malignancy.

Indexed as

Nuclear ProteinsThrombocytopeniaAdultAgedFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMiddle AgedANKRD26 protein, humanIntercellular Signaling Peptides and ProteinsNuclear Proteins

Identifiers

PMID40331912
PMCPMC12333224

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.